BakerTilly has analysed the MHealth sector , Mobile Health o Mobile Health, with the aim of identifying what has been invested in, how and at what stage, i.e. what have been the investment trends in the sector over the last decade.
MHealth has been discussed previously in other posts and as mentioned, this sector includes all those companies dedicated to the development of mobile technology to manage people's health and wellbeing. This technology can be used by both healthcare employees and patients to collect, store and analyse information related to their health.
On this occasion, we have analysed the 443 active companies listed under the "MHealth" label, of which 400 have been created in the last decade. In other words, almost 85 % of the companies dedicated to Mobile Health are very recent start-ups. This shows us that this is a new and growing market, which may lead us to identify some investment opportunities in the sector.
Since 2010 there have been 91 rounds of funding in the sector globally, of which 44, or almost half, have taken place in stages. Seed. A further 18 rounds have been launched in the early stages or Early Stages.
Through all these rounds, the sector has raised more than $270 million in funding.
To conclude, we will analyse which have been the investments most relevant rounds in the last year. The most capital-intensive round was that of the British medical services company Zavawhich raised $32 million in funding in its first round in 2019. No other round has been as intensive as this one in MHealth or Mobile Health. However, there have been a few others that have been of outstanding relevance for having been carried out in highly innovative companies with great added value for the sector.
For example, Altoidaa company dedicated exclusively to brain health, raised $6.3 million in funding in its A round, enabling it to continue research into a cure for Alzheimer's disease. The company, which develops solutions for remote patient monitoring, has raised $6.3 million in funding in its A round, enabling it to continue research into a cure for Alzheimer's. Somatix also launched its A round in 2019, receiving $6 million in funding.